A framework for outpatient CAR-T monitoring to support Canadian CAR-T capacity building
Abstract
Introduction: why outpatient CAR-T therapy now in Canada?
Chimeric antigen receptor T cell (CAR-T) therapy has significantly improved outcomes, including sustained remissions and even cures, for patients with refractory or relapsed B-cell non-Hodgkin lymphoma (NHL), B-cell acute lymphoblastic leukemia (ALL), and multiple myeloma (MM).1-8 CAR-T products differ by antigen target, such as CD19 and B cell maturation antigen (BCMA); and by co-stimulatory domain, which is either CD28 (e.g., axicabtagene ciloleucel, brexucabtagene autoleucel) or 4-1BB (e.g., tisagenlecleucel, lisocabtagene maraleucel, idecabtagene vicleucel). Prior to CAR-T availability, patients with relapsed hematologic malignancies experienced poor outcomes. For example, in patients with relapsed/refractory large B-cell lymphomas, the median overall survival was 6.2 months. prior to access to CAR-T therapy.9 These outcomes are balanced by CAR-T therapy-associated toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Despite the substantial clinical benefits observed with CAR T-cell therapy, treatment is associated with distinct immune-mediated toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANs). Although these adverse events are generally manageable with established treatment algorithms and are often reversible, severe toxicities, resulting in organ dysfunction and occasionally death, may occur and can necessitate ICU-level care. Enhanced understanding of toxicity kinetics, earlier intervention strategies, and the availability of effective management approaches such as tocilizumab and corticosteroids have improved the safety profile of CAR T-cell therapy. Early interventions, such as tocilizumab (anti-IL-6R) and corticosteroids, can attenuate the severity of these toxicities. Given the potential for severe toxicities, CAR-T has traditionally been administered and monitored in an inpatient hospital setting.
References
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-52.
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294-308.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. New Engl J Med. 2020;382(14):1331-42.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult relapsed or refractory diffuse large B-cell lymphoma. New Engl J Med. 2019;380(1):45-56.
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New Engl J Med. 2018;378(5):439-48.
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91-103.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New Engl J Med. 2017;377(26):2531-44.
Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. New Engl J Med. 2022;386(7):640-54.
Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-8.
Kish J, Liu R, Pfeffer D, Vennam S, Lussier C, Nayak P. Real-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies. J Clin Oncol. 2023;41(16_suppl):e18896-e.
Bakalov V, Tang A, Helfand AM, Kancharla P, White R, Khattab A, et al. A national inpatient sample analysis for CAR-T cell therapy administration. J Clin Oncol. 2022;40(16_suppl):e19501-e.
Gupta A, Eisenhauer EA, Booth CM. The time toxicity of cancer treatment. J Clin Oncol. 2022;40(15):1611-5.
Ahmed N, Sun F, Teigland C, Kilgore KM, Mohammadi I, Chambers J, et al. Chimeric Antigen receptor T-cell Access in patients with relapsed/refractory large B-cell lymphoma: association of access with social determinants of health and travel time to treatment centers. Transplant Cell Ther. 2024;30(7):714-25.
Buecklein VL, Ayuk FA, Holderried TAW, Mai C, Kievit B, Blisset R, et al. Estimating the impact on survival of not receiving CAR T therapy despite being eligible in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients in Germany. Blood. 2024;144:5037.
Dashboard. CCS. Incidence for selected cancers, by geographic region, and sex [Available from: https://cancerstats.ca/Incidence/Region].
Science IIfHD. Strengthening Pathways for cell and gene therapies: current state and future scenarios 2025 [Available from: www.iqviainstitute.org].
Simmons GL, Cross S, Pittos EC. Advancing access to CAR T-cell therapy: insights and real-world experience from a community oncology practice. Front Oncol. 2026;16:1712533.
Ly A, Sanber K, Tsai H-L, Ondo A, Mooney K, Shedeck A, et al. Outpatient CD19-directed CAR T-cell therapy is feasible in patients of all ages. Br J Haematol. 2023;203(4):688-92.
Linhares Y, Freytes CO, Cherry M, Bachier C, Maris M, Hoda D, et al. OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL. Blood Adv. 2024;8(23):6114-26.
Cox T, Carelock T, Zahradka N, Pugmire J, Wilkes M, Campo R, et al. Remote patient monitoring (RPM) technology with centralized virtual nurse monitoring for safe delivery of outpatient chimeric antigen receptor T-cell (CAR-T) Therapy across multiple sarah cannon transplant and cellular therapy network programs. Transplant Cell Ther. 2024;30(2, Supplement):S216-7.
Borogovac A, Keruakous A, Bycko M, Holter Chakrabarty J, Ibrahimi S, Khawandanah M, et al. Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center. Bone Marrow Transplant. 2022;57(6):1025-7.
Ahmed N, Wesson W, Mushtaq MU, Porter DL, Nasta SD, Brower J, et al. Patient Characteristics and outcomes of outpatient tisagenlecleucel recipients for B cell non-Hodgkin lymphoma. Transplant Cell Ther. 2023;29(7):449.e1-7.
Dholaria B, Bhaskar ST, Patel VG, Biltibo E, Jayani R, Sengsayadeth S, et al. Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial. Bone Marrow Transplant. 2025;60(6):769-72.
Leslie L, Tees M, Flinn IW, Rodriguez TE, Baird JH, Deol A, et al. ZUMA-24: A phase 2, open-label study of axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma given outpatient with corticosteroids. Hematol Oncol. 2023;41(S2):843-5.
Ohuabunwa I, Dholaria B, Wanca M, Johnson Mercadante G, Akhom P, Baer B, et al. Feasibility of outpatient administration of ciltacabtagene autoleucel and reduction in healthcare utilization cost: the Vanderbilt experience. Bone Marrow Transplant. 2026;61(3):358-9.
Rajeeve S, Wilkes M, Zahradka N, Tomalin L, Quidwai M, Pan D, et al. Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma. JCI Insight. 2026;11(12):e203988.
Battiwalla M, Egloff SA, Nadimpalli G, Martin C, Blunk B, Culos K, et al. Outpatient versus inpatient axicabtagene ciloleucel CAR T-cell therapy in non-Hodgkin’s lymphoma: insights from a US multicenter transplant and cellular therapy network. Transplant Cell Ther. 2026;32(7):862.e1-.e14.
Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, et al. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024;8(16):4320-9.
Dholaria B, Bhaskar ST, Patel VG, Biltibo E, Jayani R, Sengsayadeth S, et al. Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial. Bone Marrow Transplant. 2025;60(6):769-72.
Hansen DK, Liu Y-H, Ranjan S, Bhandari H, Potluri R, McFarland L, et al. The Impact of outpatient versus inpatient administration of CAR-T therapies on clinical, economic, and humanistic outcomes in patients with hematological cancer: a systematic literature review. Cancers. 2023;15(24):5746.
Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma. JAMA Netw Open. 2020;3(4):e202072-e.
Oluwole OO, Dholaria B, Knight TE, Jain T, Locke FL, Ramsdell L, et al. Chimeric antigen receptor T-cell therapy in the outpatient setting: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2024;30(2):131-42.
Majhail NS, Cox T, Larson S, Battiwalla M, Ramakrishnan A, Shaughnessy P, et al. Outpatient administration of chimeric antigen receptor T-cell therapy using remote patient monitoring. JCO Oncol Pract. 2025;21(11):1601-8.
Hunter BD, Lunning M, Shadman M, Ahmed S, Abramson JS, Perales MA, et al. CRS or ICANS are rare beyond 2 weeks after lisocabtagene maraleucel infusion: data from clinical trials and the real-world setting. Transplant Cell Ther. 2026;32(2):171 e1- e12.
Lemieux C, Kuruvilla J, Shafey M, Davison K, Paulson K, Li SZL, et al. Real-world outcomes of axicabtagene ciloleucel for treatment of relapsed or refractory large B-cell lymphoma in Canada. Curr Oncol. 2026;33(2):85.
Kersten MJ, Oluwole OO, Speth K, Song Q, Martin LJ, Shu D, et al. Incidence of cytokine release syndrome and neurological events in patients with relapsed or refractory large B-cell lymphoma at and beyond 2 weeks following axicabtagene ciloleucel infusion. Transplant Cell Ther. 2025;31(2):S230.
Ahmed N, Wesson W, Lutfi F, Porter DL, Bachanova V, Nastoupil LJ, et al. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 2024;8(20):5346-54.
US Food and Drug Administration. FDA expands access to approved CAR T-cell therapies by eliminating REMS. Silver Spring (MD): U.S. Food and Drug Administration; 2025. Available from:
Bristol Myers Squibb Canada. Breyanzi (lisocabtagene maraleucel) product monograph. Montreal, QC: Bristol Myers Squibb Canada; 2026.
Gilead Sciences Canada Inc. YESCARTA (axicabtagene ciloleucel) product monograph. Mississauga, ON: Gilead Sciences Canada, Inc.; 2026.
Deschenes-Simard X, Bromberg M, Devlin SM, Gonen M, Beyar-Katz O, Ip A, et al. Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma. Blood Adv. 2025;9(21):5571-84.
Looka A, Qualls DA, Matthews D, Redd RA, Sakellis C, Duffy C, et al. A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma. Blood Adv. 2025;9(3):455-62.
Portuguese AJ, Huang JJ, Jeon Y, Taheri M, Albittar A, Liang EC, et al. Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up. Haematologica. 2025;110(9):2040-54.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Canadian Hematology Today

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.